Revolution Medicines, Inc.

RVMD: NasdaqGS
8Total

Lowest reading is at 2 out of 100. All scores are out of 100.

About The Company

CEO

Dr. Mark A. Goldsmith M.D., Ph.D.

Market Cap

43.93 Billion USD

Sector

Healthcare

Website

https://www.revmed.com

Last Update

27/09/2026, 17:14:40

Description

Revolution Medicines, Inc.

Read More

Strongest readings

  • ✔Debt is low at 0.00 times equity

Weakest readings

  • ✘Returns on capital have declined over five years (13.90% lower)
  • ✘Income is not covering expenditure and investment (free cashflow -5.53 per share)
  • ✘Share count has been rising at 7.29% per year
  • ✘Earnings are negative at -3.06 per share
  • ✘Earnings and cashflow growth is weak (growth score 2 out of 100)

Key Figures

StatusMetricValueReadingMarket avg
Price / earnings (TTM)
N/A19.60x
✘
Margin of safety (DCF)
-94.07%
17.95%
✘
Revenue growth (5y average)
-14.14%
10.97%
✘
Dividend yield (TTM)
0.00%
1.85%
✘
Share count, per year
7.29%
0.00%
✘Return on capital employed-12.73%
10.00%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

Valuation

5 / 100

Priced above the market on most measures.

StatusMetricValueReadingMarket avg
Price / earnings
N/A19.60x
✘Free cashflow yield-2.70%
4.70%
Price / earnings growthN/A1.50x
Price / book16.86x
—
✘
Margin of safety
-94.07%
17.95%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Estimated intrinsic value of 12.16 USD is below the current price of 204.97 USD

Desired Margin Of Safety

0%

▼

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Estimated Fair Value: 3.3 USD ✘

Current Price: 205 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.

Growth

2 / 100

Growing more slowly than the market on most measures.

StatusMetricValueReadingMarket avg
✘
Revenue growth
-14.14%
10.97%
Earnings growthN/A14.48%
Cashflow growthN/A12.35%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Health

    not enough data

    Not enough of the underlying data is reported to score this section.

    Measured on Leverage and capital, Funding and liquidity, Earnings quality.

    StatusMetricValueReadingThreshold
    Altman-Z scoreN/A3.00
    Piotroski scoreN/A5.00
    ✔Debt / equity0.00x
    0.80x
    ✔Current ratio11.38x
    1.00x
    ✘Interest coverage-21.24x
    2.50x
    ✘Free cashflow / debt0.00x
    0.15x
    Debt / capitalN/A1.00x

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    • ✘Income is not covering expenditure and investment (free cashflow -5.53 per share)

    Management

    16 / 100

    Returns on capital are below the market.

    StatusMetricValueReadingMarket avg
    ✘Return on equity-24.72%
    15.00%
    ✘Return on capital employed-12.73%
    10.00%
    Return on assets-14.90%
    —
    Free cashflow return on capital-9.82%
    —
    ✘Return on capital, 5y change-13.90%
    0.00%
    ✘
    Share count, per year
    7.29%
    0.00%
    ✘Share count, recent1.63%
    0.00%
    Realized buyback returnN/A0.00%
    ✔Goodwill erosion / equity0.00%
    2.00%
    Price volatility, 5 year61.39%
    —

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    • ✔New shares were issued while the value score was 5 out of 100

    Analysts

    not enough data
    StatusMetricValueReadingNeutral
    Analyst opinion scoreN/A50

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Financial History

    Annual figures across the full reporting history we hold.

    Market Peers

    RVMD

    SEC Filings

    Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

    See 35+ Years Annual Reports

    Other Information

    Company Name

    Revolution Medicines, Inc.

    Currency

    USD

    Beta

    1.406

    Vol Avg

    2024030

    Ceo

    Dr. Mark A. Goldsmith M.D., Ph.D.

    Cik

    0001628171

    Cusip

    Exchange

    NasdaqGS

    Full Time Employees

    883

    Industry

    Biotechnology

    Sector

    Healthcare

    Ipo Date

    Address

    700 Saginaw Drive

    City

    Redwood City

    State

    CA

    Country

    United States

    Zip

    94063

    Phone

    650 481 6801

    Analysis Last Updated

    27/09/2026, 17:14:40

    Financial data compiled from SEC EDGAR filings and Yahoo Finance.

    Noticed an error with something on our site?

    Data, not advice. Do your own diligence.

    We Use Cookies